The Blackstone Group has announced the closing of its acquisition of Clarus. The business will now operate as Blackstone Life Sciences.
Blackstone indicated that its new private investment platform will invest across the lifecycle of companies and products within life sciences sectors.
Historical funds will retain the Clarus name.
Blackstone had previously announced its acquisition of Clarus, a global life sciences investment firm based in Cambridge, Mass., and South San Francisco, in October.
Founded in 1985, Blackstone targets investments in established and growth-oriented businesses. It’s based in New York and publicly traded under the ticker symbol BX.
